Xenon Pharmaceuticals Inc.
XENE
Rangering i aksjer
#4419
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Aksjekurs
$36.43
Sist synkronisert: 2026-10-20
Markedsverdi
$3.53B
Endring (1 dag)
3.85%
Endring (1 år)
-15.35%
Land
CA
Handel Xenon Pharmaceuticals Inc. (XENE)
Kategori
Healthcare
P/E-forhold for Xenon Pharmaceuticals Inc. (XENE)
P/E-forhold per October 2026 TTM: -7.15
Ifølge Xenon Pharmaceuticals Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -7.15. Ved slutten av 2023 hadde selskapet en P/E på -16.89.
P/E-forholdshistorikk for Xenon Pharmaceuticals Inc. fra 2011 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | -7.15 | -45.11% |
| 2024 | -13.03 | -22.86% |
| 2023 | -16.89 | -11.29% |
| 2022 | -19.04 | 10.20% |
| 2021 | -17.28 | -6.21% |
| 2020 | -18.42 | 125.34% |
| 2019 | -8.18 | 130.09% |
| 2018 | -3.55 | 114.35% |
| 2017 | -1.66 | -68.04% |
| 2016 | -5.19 | -28.84% |
| 2015 | -7.29 | -134.62% |
| 2014 | 21.06 | 165.61% |
| 2013 | 7.93 | -343.99% |
| 2012 | -3.25 | 179.21% |
| 2011 | -1.16 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 28.78 | -502.44% |
US
|
|
| -28.36 | 296.52% |
US
|
|
| -24.57 | 243.50% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -524.08% |
NL
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.